SlideShare a Scribd company logo
1 of 18
Download to read offline
“The Rising Costs of Compounded
Drugs in Health Plans:
How Best to Manage Them”
March 1, 2016
John Grossomanides, R.Ph.
Pricewaterhouse Coopers, Manager H&W
Goals & Objectives
Identify the drugs which are increasing compound costs
Quantify the amount of cost seen in compounding drugs
Provide insight as to how appropriately control these high cost agents
2
Defining Compound Drugs
As Defined by The FDA…
“Compounding is a practice in which a licensed pharmacist, a
licensed physician, or, in the case of an outsourcing facility, a person
under the supervision of a licensed pharmacist, combines, mixes, or
alters ingredients of a drug to create a medication tailored to the needs
of an individual patient”1
1. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding
3
Characteristics of Compounded Drugs
May include sterile and nonsterile preparations
Made up of active and/or inactive ingredients.
 The active ingredient or ingredients in a compounded drug may be one or
more FDA-approved products,
 Or may be bulk drug substances. (Bulk drug substances—usually raw
powders—are generally not approved by FDA for marketing in the US)
Oral liquids(Suspension/Solutions), capsules, or cream/ointments
4
Examples of compound benefits:
Adjust strength or dosage – Captopril Solution
Flavor a medication
Reformulate the drug to exclude an unwanted, nonessential
ingredient
(e.g. gluten, or a dye to which a patient may be allergic)
Change the form of the medication i.e. if they have difficulty
swallowing
Fortified Prescriptions
5
WHY is compounding a concern
 High Cost of the ingredients
 Increasing Drug Trend
 Changes in National Council for Prescription Drug Programs (NCPDP)
claims submission standards for compounded prescriptions
 Number of NDCs in First Data Bank added for bulk drug substances
grew from less <500 in 2009 to almost 2500 in 2013
 Safety
6
7
CVS Caremark Presentation, M. Shelby
8
CVS Caremark Presentation, M. Shelby
Health Plan Demographics
 100% Commercial
 170,000 lives
 3 tier copay benefit design ( $10-$30-$50)
 Open formulary
 No exclusions of therapeutic classes
9
Top cost drivers compound drugs
Gabapentin powder
Fluticasone propionate powder
Micronized Progesterone
Tobramycin Sulfate
Inactive ingredients: Flavoring agents, bases, Ethoxy Diglycol
10Internal data on file, 2007-2015
Other High Cost Drugs used in compounds
Ketamine
Flurbiprofen
Lipoderm
Meloxicam
Bupivacaine
Mometasone
ALL USED TOPICALLY FOR PAIN
11
Example of a Compound Prescription
12
International Journal of Pharmaceutical Compounding Vol.11 No.3 May/June 2007
13
Compound Cream vs. OTC product
 Medrox Rx– Manufactured for: Pharmaceutica North America Package
size: 120 grams (4 oz.) tube NDC: 45861-0005-01
 Methyl Salicylate - 20% Menthol - 5% Capsaicin - -0.035%
 AWP: $3.125/gram or $375.00 for a 120 gram tube
 Note: the percent is the number of grams of the active ingredient per 100
grams of inert cream/gel
 Compare the actual production costs as quoted to a private label OTC
pharmaceutical manufacturer for a Medrox like product: $4.91
AWP vs. Cost
14
Commercial Plan Costs Year over Year
Year 2007 2008 2009 2010 2011 2012 2013 2014
Compound
RXs
2779 1299 771 751 864 1301 2205 993
Ingredient
Cost
$674,417 $227,316 $172,194 $176,867 $169,859 $192,354 $393,407 $527,756
Average
Cost per RX
$243 $175 $223 $236 $197 $148 $178 $531
15
Internal data on file, 2007-2015
Health Plan Costs
16
Internal data on file, 2007-2015
Cost Savings Strategies
Simply Exclude Compounds from coverage
Prior Authorization
 Dollar threshold
 Prior failure of commercially available formulations
 Require supporting medical literature from peer review journal
 Coverage rules for inactive ingredients/ customized formulary
Strict Off Label use policy
RESVERATROL Anti-inflammatory dietary supplement available in over-
the-counter (OTC) formulations; not an approved drug
17
THANK YOU!!
18

More Related Content

What's hot

General Compounding PowerPoint Presentation
General Compounding PowerPoint PresentationGeneral Compounding PowerPoint Presentation
General Compounding PowerPoint PresentationRenee Moore
 
High alert & lasa medications
High alert & lasa medicationsHigh alert & lasa medications
High alert & lasa medicationsHatch Compliance
 
Proteinbindingofdrug 150217022700-conversion-gate02
Proteinbindingofdrug 150217022700-conversion-gate02Proteinbindingofdrug 150217022700-conversion-gate02
Proteinbindingofdrug 150217022700-conversion-gate02MANISH KUMAR
 
Look alike and sound alike medications
Look alike and sound alike medicationsLook alike and sound alike medications
Look alike and sound alike medicationsMEEQAT HOSPITAL
 
kinetics of drug interactions
kinetics of drug interactionskinetics of drug interactions
kinetics of drug interactions1918225
 
Protein drug binding
Protein drug bindingProtein drug binding
Protein drug bindingSnehal Patel
 
Drug protein interactions
Drug protein interactionsDrug protein interactions
Drug protein interactionsShritilekhaDash
 
Protein binding of drugs and screening of drugs by physicochemical properties
Protein binding of drugs  and screening of drugs by physicochemical propertiesProtein binding of drugs  and screening of drugs by physicochemical properties
Protein binding of drugs and screening of drugs by physicochemical propertiesBhaswat Chakraborty
 
Lasa drugs final ppt (1).pptx medcell
Lasa drugs final ppt (1).pptx medcellLasa drugs final ppt (1).pptx medcell
Lasa drugs final ppt (1).pptx medcellVir Sharma
 
Protein drug binding.ppt
Protein drug binding.pptProtein drug binding.ppt
Protein drug binding.pptram choure
 
Drug Interactions and protein drug binding interactions
Drug Interactions and protein drug binding interactionsDrug Interactions and protein drug binding interactions
Drug Interactions and protein drug binding interactionsSiva Sivappa
 
Drugs and their classification
Drugs and their classificationDrugs and their classification
Drugs and their classificationShankarBattin
 
Factors affecting protein drug binding and rotein drug binding
Factors affecting protein drug binding and rotein drug bindingFactors affecting protein drug binding and rotein drug binding
Factors affecting protein drug binding and rotein drug bindingAshwani Kumar Singh
 

What's hot (19)

General Compounding PowerPoint Presentation
General Compounding PowerPoint PresentationGeneral Compounding PowerPoint Presentation
General Compounding PowerPoint Presentation
 
High alert & lasa medications
High alert & lasa medicationsHigh alert & lasa medications
High alert & lasa medications
 
Proteinbindingofdrug 150217022700-conversion-gate02
Proteinbindingofdrug 150217022700-conversion-gate02Proteinbindingofdrug 150217022700-conversion-gate02
Proteinbindingofdrug 150217022700-conversion-gate02
 
Protein Drug Binding
Protein Drug BindingProtein Drug Binding
Protein Drug Binding
 
Look alike and sound alike medications
Look alike and sound alike medicationsLook alike and sound alike medications
Look alike and sound alike medications
 
kinetics of drug interactions
kinetics of drug interactionskinetics of drug interactions
kinetics of drug interactions
 
Protein drug binding
Protein drug bindingProtein drug binding
Protein drug binding
 
Protein binding of drugs
Protein binding of drugs   Protein binding of drugs
Protein binding of drugs
 
Drug protein interactions
Drug protein interactionsDrug protein interactions
Drug protein interactions
 
Protein binding of drugs and screening of drugs by physicochemical properties
Protein binding of drugs  and screening of drugs by physicochemical propertiesProtein binding of drugs  and screening of drugs by physicochemical properties
Protein binding of drugs and screening of drugs by physicochemical properties
 
Lasa drugs final ppt (1).pptx medcell
Lasa drugs final ppt (1).pptx medcellLasa drugs final ppt (1).pptx medcell
Lasa drugs final ppt (1).pptx medcell
 
Protein drug binding.ppt
Protein drug binding.pptProtein drug binding.ppt
Protein drug binding.ppt
 
201p (2)
201p (2)201p (2)
201p (2)
 
Bicalutmide
BicalutmideBicalutmide
Bicalutmide
 
Drug Interactions and protein drug binding interactions
Drug Interactions and protein drug binding interactionsDrug Interactions and protein drug binding interactions
Drug Interactions and protein drug binding interactions
 
LASA drugs
LASA  drugs LASA  drugs
LASA drugs
 
Drug interaction
Drug interactionDrug interaction
Drug interaction
 
Drugs and their classification
Drugs and their classificationDrugs and their classification
Drugs and their classification
 
Factors affecting protein drug binding and rotein drug binding
Factors affecting protein drug binding and rotein drug bindingFactors affecting protein drug binding and rotein drug binding
Factors affecting protein drug binding and rotein drug binding
 

Similar to John G_PBMI FEB 2016

Fixed Dose Drug Combination (FDDC)
Fixed Dose Drug Combination (FDDC)Fixed Dose Drug Combination (FDDC)
Fixed Dose Drug Combination (FDDC)Monika Singh
 
Fixed dose combination products – rationality, status in india, development i...
Fixed dose combination products – rationality, status in india, development i...Fixed dose combination products – rationality, status in india, development i...
Fixed dose combination products – rationality, status in india, development i...Dr Sukanta sen
 
Developing a pharmaceutical income generating business within synapse services
Developing a pharmaceutical income generating business within synapse servicesDeveloping a pharmaceutical income generating business within synapse services
Developing a pharmaceutical income generating business within synapse servicesOkhuosami Fatima
 
DRUG USE MEASURES.pptx
DRUG USE MEASURES.pptxDRUG USE MEASURES.pptx
DRUG USE MEASURES.pptxAmeena Kadar
 
Pharmacy Orientation - Physical Pharmacy
Pharmacy Orientation - Physical PharmacyPharmacy Orientation - Physical Pharmacy
Pharmacy Orientation - Physical PharmacyPharmoHub Pakistan
 
b. Clinical Pharmacy.pptx
b. Clinical Pharmacy.pptxb. Clinical Pharmacy.pptx
b. Clinical Pharmacy.pptxAnusha Are
 
Botanical Drug Development
Botanical Drug DevelopmentBotanical Drug Development
Botanical Drug DevelopmentPeter Pekos
 
Pharmaceutical calculations 4
Pharmaceutical calculations 4Pharmaceutical calculations 4
Pharmaceutical calculations 4Laith Alasadi
 
Pharmacy Practice (BP703T) Unit-3.pptx
Pharmacy Practice (BP703T) Unit-3.pptxPharmacy Practice (BP703T) Unit-3.pptx
Pharmacy Practice (BP703T) Unit-3.pptxSagarpamu123
 
Pharmacological classification of Drug by KD Tripathi.pdf
Pharmacological classification of Drug  by KD Tripathi.pdfPharmacological classification of Drug  by KD Tripathi.pdf
Pharmacological classification of Drug by KD Tripathi.pdfssuserc028cd
 
Pharmacological Classification of Drugs with Doses and Preparations ( PDFDriv...
Pharmacological Classification of Drugs with Doses and Preparations ( PDFDriv...Pharmacological Classification of Drugs with Doses and Preparations ( PDFDriv...
Pharmacological Classification of Drugs with Doses and Preparations ( PDFDriv...NishitJain11
 
GMP Sub Part A & B
GMP Sub Part A & BGMP Sub Part A & B
GMP Sub Part A & BHARDIK PATEL
 
Drug formulary.pptx.....................
Drug formulary.pptx.....................Drug formulary.pptx.....................
Drug formulary.pptx.....................loreensinkende
 
hospital formulary, TDM.pdf
hospital formulary, TDM.pdfhospital formulary, TDM.pdf
hospital formulary, TDM.pdfAkhilesh Kumar
 
PATIENT PACKAGE INSERT (PPI).pptx
PATIENT PACKAGE INSERT (PPI).pptxPATIENT PACKAGE INSERT (PPI).pptx
PATIENT PACKAGE INSERT (PPI).pptxLipanjali Badhei
 

Similar to John G_PBMI FEB 2016 (20)

Fixed Dose Drug Combination (FDDC)
Fixed Dose Drug Combination (FDDC)Fixed Dose Drug Combination (FDDC)
Fixed Dose Drug Combination (FDDC)
 
Fixed dose combination products – rationality, status in india, development i...
Fixed dose combination products – rationality, status in india, development i...Fixed dose combination products – rationality, status in india, development i...
Fixed dose combination products – rationality, status in india, development i...
 
Developing a pharmaceutical income generating business within synapse services
Developing a pharmaceutical income generating business within synapse servicesDeveloping a pharmaceutical income generating business within synapse services
Developing a pharmaceutical income generating business within synapse services
 
DRUG USE MEASURES.pptx
DRUG USE MEASURES.pptxDRUG USE MEASURES.pptx
DRUG USE MEASURES.pptx
 
Pharmacy Orientation - Physical Pharmacy
Pharmacy Orientation - Physical PharmacyPharmacy Orientation - Physical Pharmacy
Pharmacy Orientation - Physical Pharmacy
 
b. Clinical Pharmacy.pptx
b. Clinical Pharmacy.pptxb. Clinical Pharmacy.pptx
b. Clinical Pharmacy.pptx
 
Botanical Drug Development
Botanical Drug DevelopmentBotanical Drug Development
Botanical Drug Development
 
Pharmaceutical calculations 4
Pharmaceutical calculations 4Pharmaceutical calculations 4
Pharmaceutical calculations 4
 
Thunga thanmayee
Thunga thanmayeeThunga thanmayee
Thunga thanmayee
 
Hospital formulary
Hospital formularyHospital formulary
Hospital formulary
 
Rational Therapeutics (2)
Rational  Therapeutics (2)Rational  Therapeutics (2)
Rational Therapeutics (2)
 
Pharmacy Practice (BP703T) Unit-3.pptx
Pharmacy Practice (BP703T) Unit-3.pptxPharmacy Practice (BP703T) Unit-3.pptx
Pharmacy Practice (BP703T) Unit-3.pptx
 
Records and reports
Records  and  reportsRecords  and  reports
Records and reports
 
Pharmacological classification of Drug by KD Tripathi.pdf
Pharmacological classification of Drug  by KD Tripathi.pdfPharmacological classification of Drug  by KD Tripathi.pdf
Pharmacological classification of Drug by KD Tripathi.pdf
 
Pharmacological Classification of Drugs with Doses and Preparations ( PDFDriv...
Pharmacological Classification of Drugs with Doses and Preparations ( PDFDriv...Pharmacological Classification of Drugs with Doses and Preparations ( PDFDriv...
Pharmacological Classification of Drugs with Doses and Preparations ( PDFDriv...
 
GMP Sub Part A & B
GMP Sub Part A & BGMP Sub Part A & B
GMP Sub Part A & B
 
Clinical pharmacy 1
Clinical pharmacy 1Clinical pharmacy 1
Clinical pharmacy 1
 
Drug formulary.pptx.....................
Drug formulary.pptx.....................Drug formulary.pptx.....................
Drug formulary.pptx.....................
 
hospital formulary, TDM.pdf
hospital formulary, TDM.pdfhospital formulary, TDM.pdf
hospital formulary, TDM.pdf
 
PATIENT PACKAGE INSERT (PPI).pptx
PATIENT PACKAGE INSERT (PPI).pptxPATIENT PACKAGE INSERT (PPI).pptx
PATIENT PACKAGE INSERT (PPI).pptx
 

John G_PBMI FEB 2016

  • 1. “The Rising Costs of Compounded Drugs in Health Plans: How Best to Manage Them” March 1, 2016 John Grossomanides, R.Ph. Pricewaterhouse Coopers, Manager H&W
  • 2. Goals & Objectives Identify the drugs which are increasing compound costs Quantify the amount of cost seen in compounding drugs Provide insight as to how appropriately control these high cost agents 2
  • 3. Defining Compound Drugs As Defined by The FDA… “Compounding is a practice in which a licensed pharmacist, a licensed physician, or, in the case of an outsourcing facility, a person under the supervision of a licensed pharmacist, combines, mixes, or alters ingredients of a drug to create a medication tailored to the needs of an individual patient”1 1. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding 3
  • 4. Characteristics of Compounded Drugs May include sterile and nonsterile preparations Made up of active and/or inactive ingredients.  The active ingredient or ingredients in a compounded drug may be one or more FDA-approved products,  Or may be bulk drug substances. (Bulk drug substances—usually raw powders—are generally not approved by FDA for marketing in the US) Oral liquids(Suspension/Solutions), capsules, or cream/ointments 4
  • 5. Examples of compound benefits: Adjust strength or dosage – Captopril Solution Flavor a medication Reformulate the drug to exclude an unwanted, nonessential ingredient (e.g. gluten, or a dye to which a patient may be allergic) Change the form of the medication i.e. if they have difficulty swallowing Fortified Prescriptions 5
  • 6. WHY is compounding a concern  High Cost of the ingredients  Increasing Drug Trend  Changes in National Council for Prescription Drug Programs (NCPDP) claims submission standards for compounded prescriptions  Number of NDCs in First Data Bank added for bulk drug substances grew from less <500 in 2009 to almost 2500 in 2013  Safety 6
  • 9. Health Plan Demographics  100% Commercial  170,000 lives  3 tier copay benefit design ( $10-$30-$50)  Open formulary  No exclusions of therapeutic classes 9
  • 10. Top cost drivers compound drugs Gabapentin powder Fluticasone propionate powder Micronized Progesterone Tobramycin Sulfate Inactive ingredients: Flavoring agents, bases, Ethoxy Diglycol 10Internal data on file, 2007-2015
  • 11. Other High Cost Drugs used in compounds Ketamine Flurbiprofen Lipoderm Meloxicam Bupivacaine Mometasone ALL USED TOPICALLY FOR PAIN 11
  • 12. Example of a Compound Prescription 12 International Journal of Pharmaceutical Compounding Vol.11 No.3 May/June 2007
  • 13. 13 Compound Cream vs. OTC product  Medrox Rx– Manufactured for: Pharmaceutica North America Package size: 120 grams (4 oz.) tube NDC: 45861-0005-01  Methyl Salicylate - 20% Menthol - 5% Capsaicin - -0.035%  AWP: $3.125/gram or $375.00 for a 120 gram tube  Note: the percent is the number of grams of the active ingredient per 100 grams of inert cream/gel  Compare the actual production costs as quoted to a private label OTC pharmaceutical manufacturer for a Medrox like product: $4.91
  • 15. Commercial Plan Costs Year over Year Year 2007 2008 2009 2010 2011 2012 2013 2014 Compound RXs 2779 1299 771 751 864 1301 2205 993 Ingredient Cost $674,417 $227,316 $172,194 $176,867 $169,859 $192,354 $393,407 $527,756 Average Cost per RX $243 $175 $223 $236 $197 $148 $178 $531 15 Internal data on file, 2007-2015
  • 16. Health Plan Costs 16 Internal data on file, 2007-2015
  • 17. Cost Savings Strategies Simply Exclude Compounds from coverage Prior Authorization  Dollar threshold  Prior failure of commercially available formulations  Require supporting medical literature from peer review journal  Coverage rules for inactive ingredients/ customized formulary Strict Off Label use policy RESVERATROL Anti-inflammatory dietary supplement available in over- the-counter (OTC) formulations; not an approved drug 17